open access

Vol 23, No 6 (2018)
Special Issue Papers
Published online: 2018-11-01
Submitted: 2017-11-15
Get Citation

The current status of immunotherapy for cervical cancer

Cecilia Orbegoso, Krithika Murali, Susana Banerjee
DOI: 10.1016/j.rpor.2018.05.001
·
Rep Pract Oncol Radiother 2018;23(6):580-588.

open access

Vol 23, No 6 (2018)
Special Issue Papers
Published online: 2018-11-01
Submitted: 2017-11-15

Abstract

Background

Immunotherapy has been proven effective in several tumours, hence diverse immune checkpoint inhibitors are currently licensed for the treatment of melanoma, kidney cancer, lung cancer and most recently, tumours with microsatellite instability. There is much enthusiasm for investigating this approach in gynaecological cancers and the possibility that immunotherapy might become part of the therapeutic landscape for gynaecological malignancies.

Cervical cancer is the fourth most frequent cancer in women worldwide and represents 7.9% of all female cancers with a higher burden of the disease and mortality in low- and middle-income countries. Cervical cancer is largely a preventable disease, since the introduction of screening tests, the recognition of the human papillomavirus (HPV) as an etiological agent, and the subsequent development of primary prophylaxis against high risk HPV subtypes. Treatment for relapsed/advanced disease has improved over the last 5 years, since the introduction of antiangiogenic therapy. However, despite advances, the median overall survival for advanced cervical cancer is 16.8 months and the 5-year overall survival for all stages is 68%. There is a need to improve outcomes and immunotherapy could offer this possibility. Clinical trials aim to understand the best timing for immunotherapy, either in the adjuvant setting or recurrent disease and whether immunotherapy, alone or in combination with other agents, improves outcomes.

Abstract

Background

Immunotherapy has been proven effective in several tumours, hence diverse immune checkpoint inhibitors are currently licensed for the treatment of melanoma, kidney cancer, lung cancer and most recently, tumours with microsatellite instability. There is much enthusiasm for investigating this approach in gynaecological cancers and the possibility that immunotherapy might become part of the therapeutic landscape for gynaecological malignancies.

Cervical cancer is the fourth most frequent cancer in women worldwide and represents 7.9% of all female cancers with a higher burden of the disease and mortality in low- and middle-income countries. Cervical cancer is largely a preventable disease, since the introduction of screening tests, the recognition of the human papillomavirus (HPV) as an etiological agent, and the subsequent development of primary prophylaxis against high risk HPV subtypes. Treatment for relapsed/advanced disease has improved over the last 5 years, since the introduction of antiangiogenic therapy. However, despite advances, the median overall survival for advanced cervical cancer is 16.8 months and the 5-year overall survival for all stages is 68%. There is a need to improve outcomes and immunotherapy could offer this possibility. Clinical trials aim to understand the best timing for immunotherapy, either in the adjuvant setting or recurrent disease and whether immunotherapy, alone or in combination with other agents, improves outcomes.

Get Citation

Keywords

APC; CAR; CD4, -8, -80; CTL; CTLA-4; DC; DFS; DNA; FIGO; HLA; HPV; IL-2; LLO; ILT' s; Lm; MAGE-A3; MCH; ORR; OS; PD-1; PD-L1; PFS; RNA; SLP; TCR; TGFβ; TILs; TRAEs; Cervical cancer; Human papillomavirus; Therapeutic vaccines; Adoptive T cell therapy; Immune checkpoints inhibitors

About this article
Title

The current status of immunotherapy for cervical cancer

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 23, No 6 (2018)

Pages

580-588

Published online

2018-11-01

DOI

10.1016/j.rpor.2018.05.001

Bibliographic record

Rep Pract Oncol Radiother 2018;23(6):580-588.

Keywords

APC
CAR
CD4
-8
-80
CTL
CTLA-4
DC
DFS
DNA
FIGO
HLA
HPV
IL-2
LLO
ILT's
Lm
MAGE-A3
MCH
ORR
OS
PD-1
PD-L1
PFS
RNA
SLP
TCR
TGFβ
TILs
TRAEs
Cervical cancer
Human papillomavirus
Therapeutic vaccines
Adoptive T cell therapy
Immune checkpoints inhibitors

Authors

Cecilia Orbegoso
Krithika Murali
Susana Banerjee

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl